Platelet GP IIb/IIIa receptor inhibition by Eptifibatide in non ST-elevation MI-acute coronary syndrome

Iranian Cardiovascular Research Journal

Volumn 3, Issue 2, 2009, Pages 86-90

  Momtahen, Mahmoud ^a   Abdi, S ^a   Javadzadeh, F ^a   Farsad, B F ^a   Sharifan, D ^a   Kazzazi, A S ^a   Momtahen, S ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute coronary syndrome; Eptifibatide; GP IIb IIIa receptor inhibitor

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR; TROPONIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; EPISTAXIS; FEMALE; GINGIVA BLEEDING; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION;

EID: 70149114835     PISSN: 1735885X     EISSN: 17358868     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Chesebro JH, Fuster V. Thrombosis in unstable angina. N Engle J Med 1992;327:192-4.
2. Braunwald E. Unstable angina: an etiologic approach to management. Circulation 1998;98:2219-22.
3. Philips DR, Scarbrough RM. Clinical pharmacology of Eptifibatide. Am J Cardiol 1997;80:11B-20B.
4. Denis MS,Henzel WJ, Pitti RM, et al. Platelet glycoprotein IIb/IIIa Protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci U S A 1990; 87:2471-75.
5. Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists. Peptide antagonist with high specificity for glycoprotein IIb/IIIa. J Biol Chem 1993;268:1066-73.
6. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-e157.
7. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660.
8. ESPRIT Investigators. Novel dosing regimen of Eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2000;356:2037-44.
9. Harrington RA. Design and methodology of the PURSUIT trial: evaluating Eptifibatide for acute ischemic coronary syndromes. Am J cardiol 1997;80:34B-38B.
10. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-43.
11. The platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators: Inhibition of the Platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable Angina and non-Q-Wave myocardial infarction. N Engl J Med 1998;338:1488-97.
12. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295:1531-8.
13. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349:1422-8.
14. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35.
15. Tricoci P, Newby LK, Kandzari DE, et al. Present and evolving role of Eptifibatide in the treatment of acute coronary syndromes. Expert Rev Cardiovasc Ther 2007;5:401-12.
16. Curran MP, Keating GM. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs 2005;65:2009-35.
17. The platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Eng J Med 1998; 338:1498-505.
18. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 1998;97:2386-95.
19. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 1996; 335:775-82.
20. Plosker GL, Ibbotson T. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes. Pharmacoeconomics 2003;21:885-912.
21. Théroux P, Labarthe B. Coping with new challenges in acute coronary syndromes. Can J Cardiol 2006;22:13c-20c.
22. Demirkan B, Guray Y, Guray U, Korkmaz S. Differential diagnosis and management of acute profound thrombocytopenia by tirofiban: a case report. J Thromb Thrombolysis 2006;22:77-8.
23. Cannon CP. Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: Insights from the TACTICS TIMI-18 trial. J Am Coll Cardiol 2003;41:43s-48s.
24. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 2007; 297:591-602.
25. Mahaffey KW, Harrington RA. Optimal timing for use of glycoprotein IIb/ IIIa inhibitors in acute coronary syndromes: questions, answers, and more questions. JAMA 2007;297:636-9.